Document Detail

Evaluation of androgens in the scalp hair and plasma of patients with male-pattern baldness before and after finasteride administration.
MedLine Citation:
PMID:  16536818     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Finasteride, a competitive inhibitor of the enzyme 5alpha-reductase II, is widely used as a medical treatment for patients with male-pattern baldness (MPB), which is affected by the distribution of androgenic steroids. It is also notable that the androgenic effect in MPB is different for each region of the head. OBJECTIVES: To study the effect of the drug finasteride, we quantified androgenic steroids in the vertex and occipital scalp hair and in the plasma of patients with MPB. METHODS: The patients with MPB, aged 23-52 years, were treated with finasteride 1 mg daily for 5 months. The hair and plasma samples were hydrolysed, extracted with n-pentane, and derivatized with MSTFA:NH4I:DTE (1000:4:5, v/w/w). We analysed the concentrations of dihydrotestosterone (DHT) and testosterone (T) in the hair and plasma using gas chromatography-mass spectrometry (GC-MS). RESULTS: In the hair, the ratio of DHT/T was decreased in the vertex scalp hair after the individual received finasteride (P < 0.005). However, we found no significant difference in the ratio of DHT/T in the occipital scalp hair before and after individuals received finasteride. Like the results in the vertex scalp hair, the ratio of DHT/T in the plasma was remarkably decreased after finasteride administration (P < 0.001). CONCLUSIONS: This study supports the effect of finasteride in patients with MPB by examining the decreased level of DHT/T in scalp hair and in plasma. Thus, in view of the androgenic effect in the different hair regions, the vertex scalp hair plays a more important role for patients with MPB treated with finasteride than does the occipital hair.
H K Ryu; K M Kim; E A Yoo; W Y Sim; B C Chung
Related Documents :
21178528 - Monitoring of plasma creatinine and urinary γ-glutamyl transpeptidase improves detecti...
2857728 - Endocrine and biochemical studies in a 46,xy phenotypically male infant with 17-ketoste...
2498378 - Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese wo...
21832308 - Microwave engineering of plasma-assisted cvd reactors for diamond deposition.
11294698 - Measurement of free and complexed soluble vascular endothelial growth factor receptor, ...
16337848 - Distribution of urinary selenium and arsenic among pregnant women exposed to arsenic in...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The British journal of dermatology     Volume:  154     ISSN:  0007-0963     ISO Abbreviation:  Br. J. Dermatol.     Publication Date:  2006 Apr 
Date Detail:
Created Date:  2006-03-15     Completed Date:  2006-08-09     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0004041     Medline TA:  Br J Dermatol     Country:  England    
Other Details:
Languages:  eng     Pagination:  730-4     Citation Subset:  IM    
Bioanalysis and Biotransformation Research Centre, Korea Institute of Science and Technology, PO Box 131, Cheongryang, Seoul, 130-605, Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Alopecia / blood,  drug therapy,  metabolism*
Dihydrotestosterone / blood,  metabolism*
Enzyme Inhibitors / pharmacology*,  therapeutic use
Finasteride / pharmacology*,  therapeutic use
Gas Chromatography-Mass Spectrometry
Hair / metabolism*
Middle Aged
Scalp / metabolism
Testosterone / blood,  metabolism*
Testosterone 5-alpha-Reductase / antagonists & inhibitors
Reg. No./Substance:
0/Enzyme Inhibitors; 521-18-6/Dihydrotestosterone; 58-22-0/Testosterone; 98319-26-7/Finasteride; EC 5-alpha-Reductase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Etanercept: effective in the management of hidradenitis suppurativa.
Next Document:  A distinctive erythematous macular exanthem of the adult: a new entity?